Vir Biotechnology has dosed the first patient in a Phase I VIR-5500 expansion cohort for metastatic prostate cancer. The trial is evaluating VIR-5500 as monotherapy and in combination settings across mCRPC and mHSPC.
Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597369 |
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07593079 |
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07590934 |
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07567846 |
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07560215 |
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort |
NOT_YET_RECRUITING | |
| NCT07529717 |
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07484269 |
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan |
NOT_YET_RECRUITING | |
| NCT07414940 |
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium |
RECRUITING | PHASE1/PHASE2 |
| NCT07389512 |
Pharmaceutical Management in Targeted Radioligand Therapy |
RECRUITING | |
| NCT07352748 |
Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa |
ACTIVE_NOT_RECRUITING |
